Retrophin to Report Third Quarter 2017 Financial Results
SAN DIEGO, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Retrophin (NASDAQ:RTRX) today announced it will report third quarter 2017 financial results on Tuesday, November 7, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
Conference Call Information
| Date: | Tuesday, November 7, 2017 |
| Time: | 4:30 p.m. ET |
| Dial-in numbers: | +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) |
| Confirmation code: | 3889648 |
| Live webcast: | Retrophin.com in the "Events & Presentations" section of the "Investors" page |
A replay of the call will be available from 7:30 p.m. ET, November 7, 2017 to 7:30 p.m. ET, November 14, 2017. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 3889648.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare diseases. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research exploring additional rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam® and Thiola®.
Chris Cline, CFA
Vice President, Investor Relations & Corporate Communications
646-564-3680
IR@retrophin.com